Avaliacao da Relacao entre a Doenca Hepatica Nao Gordurosa e CAD utilizando TCMF

Fundamento: Alguns fatores de risco para a aterosclerose são acompanhados pela doença hepática gordurosa não alcoólica (DHGNA). Desejamos usar a tomografia computadorizada multi-fatias (TCMF) como a técnica para encontrar relação entre a DHGNA e a doença arterial coronariana (DAC). Objetivo: A relação entre a DHGNA e a DAC foi investigada através de TCMF. Métodos: Um total de 372 indivíduos com ou sem sintomas cardíacos, que foram submetidos à angiografia por TCMF, foram incluídos no estudo. Os pacientes foram divididos em dois grupos, de acordo com a presença da DHGNA. Os segmentos arteriais coronarianos foram avaliados visualmente via angiografia por TCMF. Com base no grau de estenose arterial coronariana, aqueles com placas ausentes ou mínimas foram considerados como normais, enquanto aqueles que apresentavam estenose de menos do que 50% e no mínimo uma placa foram considerados como portadores da doença arterial coronariana não obstrutiva (não-obsDAC). Os pacientes que apresentaram no mínimo uma placa e estenose arterial coronariana de 50% ou mais foram considerados como portadores de doença arterial coronariana obstrutiva (obsDAC). A DHGNA foi determinada de acordo com o protocolo de TCMF, utilizando a densidade hepática. Resultados: De acordo com a densidade hepática, o número de pacientes com doença hepática gordurosa não alcoólica (grupo 1) foi de 204 (149 homens, 54,8%) e com fígado normal (grupos 2) foi de 168 (95 homens, 45.2%). Houve 50 (24,5%) não-obsDAC e 57 (27,9%) casos de obsDAC no Grupo 1, e 39 (23,2%) não-obsDAC e 23 (13,7%) casos de obsDAC no Grupo 2. Conclusões: O presente estudo utilizando TCMF demonstrou que a frequência da doença arterial coronariana em pacientes com NAFDL foi significativamente superior do que nos pacientes em NAFDL.

Effects of PDE type 5 inhibitors on Left Ventricular Diastolic Dysfunction in Resistant Hypertension

Resistant hypertension (RHTN) is a multifactorial disease characterized by blood pressure (BP) levels above goal (140/90 mmHg) in spite of the concurrent use of three or more antihypertensive drugs of different classes. Moreover, it is well known that RHTN subjects have high prevalence of left ventricular diastolic dysfunction (LVDD), which leads to increased risk of heart failure progression. This review gathers data from studies evaluating the effects of phosphodiesterase-5 (PDE-5) inhibitors (administration of acute sildenafil and short-term tadalafil) on diastolic function, biochemical and hemodynamic parameters in patients with RHTN. Acute study with sildenafil treatment found that inhibition of PDE-5 improved hemodynamic parameters and diastolic relaxation. In addition, short-term study with the use of tadalafil demonstrated improvement of LVDD, cGMP and BNP-32 levels, regardless of BP reduction. No endothelial function changes were observed in the studies. The findings of acute and short-term studies revealed potential therapeutic effects of IPDE-5 drugs on LVDD in RHTN patients.

Transcatheter Aortic Valve Implantation and Morbidity and Mortality-Related Factors: a 5-Year Experience in Brazil

Abstract Background: Transcatheter aortic valve implantation has become an option for high-surgical-risk patients with aortic valve disease. Objective: To evaluate the in-hospital and one-year follow-up outcomes of transcatheter aortic valve implantation. Methods: Prospective cohort study of transcatheter aortic valve implantation cases from July 2009 to February 2015. Analysis of clinical and procedural variables, correlating them with in-hospital and one-year mortality. Results: A total of 136 patients with a mean age of 83 years (80-87) underwent heart valve implantation; of these, 49% were women, 131 (96.3%) had aortic stenosis, one (0.7%) had aortic regurgitation and four (2.9%) had prosthetic valve dysfunction. NYHA functional class was III or IV in 129 cases (94.8%). The baseline orifice area was 0.67 ± 0.17 cm2 and the mean left ventricular-aortic pressure gradient was 47.3±18.2 mmHg, with an STS score of 9.3% (4.8%-22.3%). The prostheses implanted were self-expanding in 97% of cases. Perioperative mortality was 1.5%; 30-day mortality, 5.9%; in-hospital mortality, 8.1%; and one-year mortality, 15.5%. Blood transfusion (relative risk of 54; p = 0.0003) and pulmonary arterial hypertension (relative risk of 5.3; p = 0.036) were predictive of in-hospital mortality. Peak C-reactive protein (relative risk of 1.8; p = 0.013) and blood transfusion (relative risk of 8.3; p = 0.0009) were predictive of 1-year mortality. At 30 days, 97% of patients were in NYHA functional class I/II; at one year, this figure reached 96%. Conclusion: Transcatheter aortic valve implantation was performed with a high success rate and low mortality. Blood transfusion was associated with higher in-hospital and one-year mortality. Peak C-reactive protein was associated with one-year mortality.